Efrat Dotan

Summary

Affiliation: Fox Chase Cancer Center
Country: USA

Publications

  1. ncbi request reprint Oncologists' response to new data regarding the use of epidermal growth factor receptor inhibitors in colorectal cancer
    Efrat Dotan
    Fox Chase Cancer Center, Philadelphia, PA and University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH
    J Oncol Pract 10:308-14. 2014
  2. ncbi request reprint Patterns of use and tolerance of anti-epidermal growth factor receptor antibodies in older adults with metastatic colorectal cancer
    Efrat Dotan
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA Electronic address
    Clin Colorectal Cancer 13:192-8. 2014
  3. pmc A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study
    Efrat Dotan
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    J Gastrointest Cancer 43:562-9. 2012
  4. pmc Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer
    E Dotan
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Br J Cancer 106:748-55. 2012
  5. pmc Challenges in the management of older patients with colon cancer
    Efrat Dotan
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    J Natl Compr Canc Netw 10:213-24; quiz 225. 2012
  6. pmc Challenges in the management of stage II colon cancer
    Efrat Dotan
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Semin Oncol 38:511-20. 2011
  7. pmc Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity
    Elizabeth R Plimack
    Elizabeth R Plimack, Rosalia Viterbo, Eric A Ross, Richard E Greenberg, David Y T Chen, Yu Ning Wong, Alexander Kutikov, Efrat Dotan, Essel Dulaimi, Reza Mehrazin, Robert G Uzzo, and Gary R Hudes, Fox Chase Cancer Center, Temple Health Jean H Hoffman Censits, Edouard J Trabulsi, Costas D Lallas, Jianqing Lin, and William Kevin Kelly, Thomas Jefferson University Hospital, Philadelphia, PA Timothy A Brennan and Norma Palma, Foundation Medicine, Cambridge, MA and Stephen A Boorjian, Mayo Clinic, Rochester, MN
    J Clin Oncol 32:1895-901. 2014
  8. ncbi request reprint Optimizing chemotherapy regimens for patients with early-stage breast cancer
    Efrat Dotan
    Fox Chase Cancer Center, Philadelphia, PA 19111 2412, USA
    Clin Breast Cancer 10:E8-15. 2010
  9. ncbi request reprint Circulating tumor cells: evolving evidence and future challenges
    Efrat Dotan
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Oncologist 14:1070-82. 2009

Detail Information

Publications9

  1. ncbi request reprint Oncologists' response to new data regarding the use of epidermal growth factor receptor inhibitors in colorectal cancer
    Efrat Dotan
    Fox Chase Cancer Center, Philadelphia, PA and University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH
    J Oncol Pract 10:308-14. 2014
    ..Little is known about prescribers' response to new clinical data, practice guidelines, and US Food and Drug Administration (FDA) label change with regard to the use of anti-EGFR antibodies in clinical practice...
  2. ncbi request reprint Patterns of use and tolerance of anti-epidermal growth factor receptor antibodies in older adults with metastatic colorectal cancer
    Efrat Dotan
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA Electronic address
    Clin Colorectal Cancer 13:192-8. 2014
    ..We retrospectively reviewed our experience of treating elderly patients with mCRC with these agents between 2004 and 2011...
  3. pmc A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study
    Efrat Dotan
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    J Gastrointest Cancer 43:562-9. 2012
    ..This phase II study tested the efficacy and safety of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as first-line treatment for metastatic colorectal cancer patients...
  4. pmc Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer
    E Dotan
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Br J Cancer 106:748-55. 2012
    ..We correlated increased AURKA-CN in mCRC tumours with KRAS mutation status, overall and progression-free survival (OS, PFS)...
  5. pmc Challenges in the management of older patients with colon cancer
    Efrat Dotan
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    J Natl Compr Canc Netw 10:213-24; quiz 225. 2012
    ..This review provides an overview of the available data regarding the management of older adults with colon cancer in the adjuvant and metastatic settings...
  6. pmc Challenges in the management of stage II colon cancer
    Efrat Dotan
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Semin Oncol 38:511-20. 2011
    ..Additional research is necessary to clearly define the most appropriate way to use this marker and others in routine clinical practice...
  7. pmc Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity
    Elizabeth R Plimack
    Elizabeth R Plimack, Rosalia Viterbo, Eric A Ross, Richard E Greenberg, David Y T Chen, Yu Ning Wong, Alexander Kutikov, Efrat Dotan, Essel Dulaimi, Reza Mehrazin, Robert G Uzzo, and Gary R Hudes, Fox Chase Cancer Center, Temple Health Jean H Hoffman Censits, Edouard J Trabulsi, Costas D Lallas, Jianqing Lin, and William Kevin Kelly, Thomas Jefferson University Hospital, Philadelphia, PA Timothy A Brennan and Norma Palma, Foundation Medicine, Cambridge, MA and Stephen A Boorjian, Mayo Clinic, Rochester, MN
    J Clin Oncol 32:1895-901. 2014
    ....
  8. ncbi request reprint Optimizing chemotherapy regimens for patients with early-stage breast cancer
    Efrat Dotan
    Fox Chase Cancer Center, Philadelphia, PA 19111 2412, USA
    Clin Breast Cancer 10:E8-15. 2010
    ..This review summarizes the available tools that can assist in this process and provides an overview of the chemotherapy regimens approved for the adjuvant treatment of patients with early-stage breast cancer...
  9. ncbi request reprint Circulating tumor cells: evolving evidence and future challenges
    Efrat Dotan
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Oncologist 14:1070-82. 2009
    ..This review covers the different techniques available for isolation of CTCs, the clinical utility of CTCs in breast, prostate, and colon cancer, and future directions in this field...